Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity

Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic leukemia (CLL)

(2013) T. D. Shanafelt et al.   BLOOD

Chronic lymphocytic leukemia cells induce defective LFA-1-directed T-cell motility by altering Rho GTPase signaling that is reversible with lenalidomide

(2013) A. G. Ramsay et al.   BLOOD

High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells

(2013) J. H. Myklebust et al.   BLOOD

Protein Kinase C-β-Dependent Activation of NF-κB in Stromal Cells Is Indispensable for the Survival of Chronic Lymphocytic Leukemia B Cells In Vivo

(2013) Gloria Lutzny et al.   CANCER CELL

The PD-1/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia

(2013) D. Brusa et al.   HAEMATOLOGICA

Cytotoxic T cells induce proliferation of chronic myeloid leukemia stem cells by secreting interferon-γ

(2013) Christian Schürch et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Ibrutinib (PCI-32765), the First BTK (Bruton’s Tyrosine Kinase) Inhibitor in Clinical Trials

(2013) Jennifer R. Brown   Current Hematologic Malignancy Reports

Polyfunctional CD4+ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy

(2012) Z.-C. Ding et al.   BLOOD

Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention

(2012) W. J. Norde et al.   BLOOD

The role of B7 family molecules in hematologic malignancy

(2012) P. Greaves et al.   BLOOD

How I treat plasma cell leukemia

(2012) N. W. C. J. van de Donk et al.   BLOOD

T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production

(2012) J. C. Riches et al.   BLOOD

Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer

(2012) A. G. Ramsay et al.   BLOOD

Anti-tumour immunotherapy with Vγ9Vδ2 T lymphocytes: from the bench to the bedside

(2012) Mounia S. Braza et al.   BRITISH JOURNAL OF HAEMATOLOGY

Lenalidomide enhances anti-myeloma cellular immunity

(2012) Katarina Luptakova et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Durable Adoptive Immunotherapy for Leukemia Produced by Manipulation of Multiple Regulatory Pathways of CD8+ T-Cell Tolerance

(2012) M. M. Berrien-Elliott et al.   CANCER RESEARCH

Soluble CD200 Is Critical to Engraft Chronic Lymphocytic Leukemia Cells in Immunocompromised Mice

(2012) K. K. Wong et al.   CANCER RESEARCH

Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy

(2012) M. R. Green et al.   CLINICAL CANCER RESEARCH

The B7 Homologues and their Receptors in Hematologic Malignancies

(2012) Ryan A. Wilcox et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Janus Kinase Deregulation in Leukemia and Lymphoma

(2012) Edwin Chen et al.   IMMUNITY

Pathogenesis of follicular lymphoma

(2012) Robert Kridel et al.   JOURNAL OF CLINICAL INVESTIGATION

Immunotherapy earns its spot in the ranks of cancer therapy

(2012) Drew Pardoll et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2

(2012) Tadashi Yokosuka et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Cutting Edge: Cell-Extrinsic Immune Regulation by CTLA-4 Expressed on Conventional T Cells

(2012) C. J. Wang et al.   JOURNAL OF IMMUNOLOGY

Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3+ regulatory T cells

(2012) S J Coles et al.   LEUKEMIA

A restricted cell population propagates glioblastoma growth after chemotherapy

(2012) Jian Chen et al.   NATURE

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

(2012) Timothy R. Wilson et al.   NATURE

Immunology beats cancer: a blueprint for successful translation

(2012) Drew M Pardoll   NATURE IMMUNOLOGY

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

(2012) Jorge E. Cortes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Programmed Death-1 and Its Ligand Are Novel Immunotolerant Molecules Expressed on Leukemic B Cells in Chronic Lymphocytic Leukemia

(2012) Maciej Grzywnowicz et al.   PLoS One

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

(2011) J. N. Kochenderfer et al.   BLOOD

Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival

(2011) A. Hamilton et al.   BLOOD

Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia

(2011) Q. Zhou et al.   BLOOD

Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

(2011) S.-R. Woo et al.   CANCER RESEARCH

The Evolving War on Cancer

(2011) Daniel A. Haber et al.   CELL

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Expansion of a CD8+PD-1+ Replicative Senescence Phenotype in Early Stage CLL Patients Is Associated with Inverted CD4:CD8 Ratios and Disease Progression

(2011) C. Nunes et al.   CLINICAL CANCER RESEARCH

Programmed Death Ligand 1 Is Expressed by Non-Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells

(2011) D. J. Andorsky et al.   CLINICAL CANCER RESEARCH

Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy

(2011) S. A. Rosenberg et al.   CLINICAL CANCER RESEARCH

CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia

(2011) S J Coles et al.   LEUKEMIA

Cancer immunotherapy comes of age

(2011) Ira Mellman et al.   NATURE

MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers

(2011) Christian Steidl et al.   NATURE

T cell exhaustion

(2011) E John Wherry   NATURE IMMUNOLOGY

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion

(2011) R. D. Schreiber et al.   SCIENCE

Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4

(2011) O. S. Qureshi et al.   SCIENCE

T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

(2011) M. Kalos et al.   Science Translational Medicine

Chronic Lymphocytic Leukemia: An Update on Biology and Treatment

(2011) John C. Riches et al.   Current Oncology Reports

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma

(2010) M. R. Green et al.   BLOOD

Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia

(2010) Q. Zhou et al.   BLOOD

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

(2010) D. M. Benson et al.   BLOOD

PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1

(2010) M. Ghiotto et al.   INTERNATIONAL IMMUNOLOGY

Putting the brakes on BTLA in T cell–mediated cancer immunotherapy

(2010) Chrystal M. Paulos et al.   JOURNAL OF CLINICAL INVESTIGATION

BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination

(2010) Laurent Derré et al.   JOURNAL OF CLINICAL INVESTIGATION

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

(2010) Amie S. Corbin et al.   JOURNAL OF CLINICAL INVESTIGATION

BCR-ABL kinase is dead; long live the CML stem cell

(2010) Alexander Perl et al.   JOURNAL OF CLINICAL INVESTIGATION

Blockade of Programmed Death Ligand 1 Enhances the Therapeutic Efficacy of Combination Immunotherapy against Melanoma

(2010) S. Pilon-Thomas et al.   JOURNAL OF IMMUNOLOGY

The role of CD200 in immunity to B cell lymphoma

(2010) K. K. Wong et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

T-cell function in chronic lymphocytic leukaemia

(2010) John C. Riches et al.   SEMINARS IN CANCER BIOLOGY

Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy

(2009) A. G. Ramsay et al.   BLOOD

Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts

(2009) R. Le Dieu et al.   BLOOD

Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression

(2009) S. Mumprecht et al.   BLOOD

PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model

(2009) L. Zhang et al.   BLOOD

B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders

(2009) R. A. Wilcox et al.   BLOOD

Phase I Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

(2009) S. M. Ansell et al.   CLINICAL CANCER RESEARCH

Fine tuning the immune response through B7-H3 and B7-H4

(2009) Kyung H. Yi et al.   IMMUNOLOGICAL REVIEWS

CD28 and CTLA-4 coreceptor expression and signal transduction

(2009) Christopher E. Rudd et al.   IMMUNOLOGICAL REVIEWS

The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans

(2009) Cameron S. Brandt et al.   JOURNAL OF EXPERIMENTAL MEDICINE

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

(2009) Loise M. Francisco et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies

(2009) Karl S. Peggs et al.   JOURNAL OF EXPERIMENTAL MEDICINE

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology

B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells

(2008) T. Azuma et al.   BLOOD

PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma

(2008) R. Yamamoto et al.   BLOOD

Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells

(2008) Yu Liu et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies

(2008) R. Berger et al.   CLINICAL CANCER RESEARCH

B7-H1 on myeloid-derived suppressor cells in immune suppression by a mouse model of ovarian cancer

(2008) Yu Liu et al.   CLINICAL IMMUNOLOGY

Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials

(2008) Edward L. Korn et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients

(2008) T Kozako et al.   LEUKEMIA

Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)

(2008) M. Marzec et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cancer stem cells, CD200 and immunoevasion

(2008) Brian T. Kawasaki et al.   TRENDS IN IMMUNOLOGY